Hong Kong-listed biotech firms accelerate Moderna-style cancer vaccine development amid market frenzy
Following Moderna's breakthrough cancer vaccine trial, Chinese companies including Jiangsu Hengrui Pharmaceuticals and Li Ka-shing-backed CK Life Sciences are pushing forward with similar programmes. These companies have seen their stock prices surge, eyeing a large potential market given that nearly 2.6 million people die from cancer in China alone each year.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
24H Trending
-
1
According to Bloomberg Markets: Large asset managers are deleveraging in the U.S. Treasury futures market, triggered by forced selling as cash yields approach multi-year highs.
-
2
Wall Street's Rate Shock Spreads Beneath AI-Fueled Market Rally, Driven by High Oil Prices and Borrowing Costs
-
3
LAUNCHCOIN: Solana Ecosystem's "One-Click Token Issuance" Platform Analysis and Market Status
-
4
TypeSafe AI, the maker of the non-text AI model Jev, reached a valuation of $7.5 billion just weeks after its launch, with a16z leading an $870 million funding round.
-
5
DDX (DerivaDAO) Token Analysis: Mechanism, Utility, and Market Status
-
6
Regulatory Landscape of Virtual Currencies in Mainland China and Risks Associated with Using Overseas Trading Platforms
-
7
BEPR Token Analysis: Distinguishing Between Homonymous Projects and Current Market Status
-
8
iPhone Vulnerabilities Continue to Threaten Crypto Users, Older iOS Devices Remain at Risk
-
9
SKR Tokenomics Analysis: The Core Driver of the Solana Mobile Ecosystem
-
10
Hungary Needs Significant Deficit Cut For Euro Path, Magyar Says
Markets Today
Recommended Reading







